SBC Medical Group Holdings Incorporated (SBC) fair value analysis
Nasdaq · Updated 2026-11-02
SBC price how computed
Valuation status
Awaiting full valuationSBC does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $5.28
- Sector
- Industrials
- 12-month range
- $2.87–$5.69
- Market cap
- $543M
- From 52-week high
- -7.3%
- Shares outstanding
- 103M
- Rank in Industrials by quality score
- #8 of 155
Last price is our stored weekly price from 2026-10-30, older than the 2026-11-02 run that built this page; the chart runs through 2026-10-30.
SBC Medical Group Holdings Incorporated operates as a manufacturer and distributor of medical devices and supplies serving healthcare providers and patients across multiple markets. The company functions within the medical technology and industrial sectors, maintaining operations designed to support the healthcare industry's equipment and supply needs.
SBC currently ranks #8 of 155 Industrials stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $543M
- P/E (trailing)
- 11x
- Revenue (TTM)
- $175M
- Net margin
- 28.0%
- EPS (TTM)
- $0.47
- Gross margin
- 73.1%
- Debt / equity
- 0.18
- Revenue growth (3-yr avg)
- 1.3%
- Shares outstanding
- 103M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 51 · neutral
- 50-day average
- $4.87
- 200-day average
- $3.91
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-13
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-16.7%)
2026-03 ▲ beat (+10.0%)
2025-12 ▲ beat (+27.3%)
2025-09 ▲ beat (+9.1%)
2025-06 ▼ miss (-85.7%)
2025-03 ▲ beat (+90.9%)
2024-12 ▼ miss (-68.4%)
2024-09 ▼ miss (-98.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 0 hold · 0 sell (3 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $8.75
- Target vs last price
- +65.9%
What our data shows for SBC
- Our model validated 5 trailing price-to-earnings windows for SBC, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $2.87–$5.69.
- The 14-day relative strength index sits at a neutral 51.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SBC's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SBC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-11-02 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SBC stock undervalued?
SBC does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is SBC's TickrTrends verdict?
SBC is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does SBC compare to other Industrials stocks?
SBC ranks #8 of 155 Industrials stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is SBC overbought or oversold?
SBC's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does SBC report earnings next?
SBC's next earnings report is scheduled for 2026-11-13, per the published earnings calendar.
Does SBC usually beat earnings estimates?
Over its last 8 reported quarters SBC beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SBC?
Of 3 analysts covering SBC, 3 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $8.75 (+65.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.